Source record

Published by arXiv cs.MA (T1 source). The original is at https://arxiv.org/abs/2608.10175.

Pipeline notes

The summary and note below are generated by the signal pipeline — they are Beyond Desk’s reading, not quotations from the source.

Paper proposes a multi-agent LLM framework for valuing clinical-stage cross-border biotech, with layers for qualitative scientific valuation, cross-market price reconciliation, and conflict-fusion between scientific conviction and regulatory caution. Author cites a personal 127.17% return but states no AI implementation is evaluated.

Architectural design for agentic systems in domains where standard cash-flow valuation fails, anchored in the author's actual portfolio management record rather than pure speculation.

Cited by

No citations on record.